Abstract
Background: Severe pneumonia in elderly patients is characterized by dysregulated inflammatory responses and impaired immune recovery. However, the dynamic interplay between inflammatory–immune biomarkers and clinical recovery remains insufficiently elucidated from a biochemical perspective.
Methods: This prospective study included 276 elderly patients with severe pneumonia. Serial measurements of inflammatory biomarkers [C-reactive protein (CRP), procalcitonin (PCT), interleukin-6 (IL-6), and neutrophil-to-lymphocyte ratio (NLR)] and immune indicators (CD4+ T cells and natural killer cells) were performed at baseline, day 3, and end-of-treatment. Clinical recovery was evaluated using time to clinical stability, oxygenation index (PaO₂/FiO₂), and length of hospital stay. Associations between biomarker dynamics and recovery outcomes were analyzed.
Results: All inflammatory biomarkers exhibited significant declines over time, accompanied by partial restoration of immune function. Greater reductions in CRP, PCT, and IL-6 at early time points were associated with faster clinical stabilization and improved oxygenation (all P < 0.01). NLR showed a pronounced early decrease, reflecting attenuation of systemic inflammatory stress. Notably, recovery of CD4+ T cells was significantly associated with improved clinical outcomes (P = 0.001), suggesting coordinated immune reconstitution. Patients with more favorable biomarker trajectories demonstrated shorter hospitalization and earlier transition to clinical stability. These findings indicate that integrated inflammatory–immune biomarker dynamics closely reflect the biological recovery process in severe pneumonia.
Conclusions: Dynamic monitoring of inflammatory and immune biomarkers provides valuable biochemical insights into recovery trajectories in elderly patients with severe pneumonia. Combined biomarker profiling may serve as a practical tool for evaluating disease progression and guiding individualized management strategies.
Keywords
Array
Array
Array
Array
Array
References
The published articles will be distributed under the Creative Commons Attribution 4.0 International License (CC BY). It is allowed to copy and redistribute the material in any medium or format, and remix, transform, and build upon it for any purpose, even commercially, as long as appropriate credit is given to the original author(s), a link to the license is provided and it is indicated if changes were made. Users are required to provide full bibliographic description of the original publication (authors, article title, journal title, volume, issue, pages), as well as its DOI code. In electronic publishing, users are also required to link the content with both the original article published in Journal of Medical Biochemistry and the licence used.
Authors are able to enter into separate, additional contractual arrangements for the non-exclusive distribution of the journal's published version of the work (e.g., post it to an institutional repository or publish it in a book), with an acknowledgement of its initial publication in this journal.